Drug Type Monoclonal antibody |
Synonyms CTN 014, CTN014 |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Preclinical | South Korea | 31 Jul 2024 |